Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: February 29, 2000
Business Overview: Neogen operates two primary segments: Food Safety (diagnostic test kits for toxins, bacteria, and allergens) and Animal Safety (veterinary instruments and consumables). The company is based in Lansing, Michigan.
Key Financial Metrics
| Metric | Three Months Ended Feb 29, 2000 | Nine Months Ended Feb 29, 2000 |
|---|---|---|
| Sales (Revenue) | $6,276,000 | $17,042,000 |
| Gross Margin | $3,555,000 (56.6%) | $9,606,000 (56.4%) |
| Operating Income | $724,000 | $1,660,000 |
| Net Income | $627,000 | $1,773,000 |
| Diluted EPS | $0.11 | $0.30 |
| Cash & Equivalents | $1,472,000 | $1,472,000 (Balance Sheet) |
| Working Capital | $17,191,000 | $17,191,000 (Calculated) |
| Total Debt (Current + Long-Term) | $588,000 | $588,000 |
Note: Working capital calculated as Total Current Assets ($19,251,000) minus Total Current Liabilities ($2,060,000).
Material Changes vs. Prior Period
- Quarterly Revenue Growth: Sales increased 19% ($985,000) compared to the prior year quarter. Food Safety sales rose 20% and Animal Safety sales rose 17%.
- YTD Revenue Stagnation: Nine-month sales increased only 0.7% ($115,000). This was due to a 7% increase in Food Safety offset by a 5% decline in Animal Safety.
- Profitability Decline (YTD): Operating income for the nine months dropped 26% to $1,660,000 from $2,255,000 in the prior year. Net income decreased 14% to $1,773,000.
- Margin Compression: Gross margin percentage decreased slightly from 58.1% to 56.6% (quarterly) and from 58.1% to 56.4% (YTD) due to product mix changes.
- Expense Increases: Sales and marketing expenses rose significantly due to hiring for domestic and international expansion. General and administrative expenses increased due to legal fees related to Vicam litigation and senior personnel additions.
Guidance, Outlook, and Risks
- Guidance: Management explicitly states it does not provide forecasts of future financial performance.
- Acquisition: On February 17, 2000, Neogen acquired Acumedia Manufacturers, Inc. for approximately $2.85 million (cash and note), with potential earn-outs up to $1 million based on revenue. Proforma data suggests this acquisition would have increased YTD revenue to $19.6 million.
- Liquidity: The company holds $8.1 million in cash and marketable securities with $10 million in unused credit lines. Management notes these resources may be insufficient for future commercialization or acquisitions, potentially requiring equity issuance.
- Legal Proceedings: A settlement was reached on March 27, 2000, with Vicam L.P. regarding patent infringement and defamation claims. The settlement amount is undisclosed but will be recorded in the quarter ending May 31, 2000.
- Operational Risks: Sales of mycotoxin detection kits are volatile due to weather conditions. Animal Safety sales were impacted by a temporary shortage of the botulism vaccine (now resolved) and the loss of a major customer for specialty needles.
Investor Verification Checklist
- Acumedia Integration: Verify the financial impact and revenue contribution of the Acumedia acquisition in the next reporting period.
- Vicam Settlement: Monitor the Q2 2000 filing for the specific dollar amount of the Vicam settlement and its effect on net income.
- Product Mix Volatility: Assess the stability of mycotoxin test kit sales, which are highly dependent on agricultural weather conditions.
- Capital Needs: Evaluate the company's cash burn rate relative to its $8.1 million liquidity position to determine the likelihood of future equity dilution.
- Customer Concentration: Investigate the replacement of the lost $700,000 revenue stream from the specialty needle customer.